NORWALK, Conn.--While Perkin-Elmer and Hyseq,of Sunny vale, Calif., continue to streamline the sample analysis process associated with their new HyChip technology, the companies have announced that they will offer pharmaceutical research companies early access to the new universal DNA chip. Hyseq will continue to refine the HyChip sequencing chemistry in addition to the production of the chip component at its facility. Automated reagent delivery instruments and HyChip analyzers are under development at Perkin-Elmer's Applied Biosystems Division. PE Applied Biosystems will manufacture, package, and sell the DNA-target-specific labeled probes.
The companies said the HyChip will provide a significant improvement over current technologies that require specific chips to be manufactured for specific tests. Hyseq's patented Sequencing by Hybridization technology will be broadly available in point-of-use applications, the company said.
The technology utilizes a single complete set of all n-mers probes (currently, 1,024 pentamers) in conjunction with a target-specific cocktail of labeled probes and DNA ligase to identify single nucleotide differences between a reference and a test sample. The use of a universal set of probes allows for arrays to be developed at low density.